Combination of formoterol and tiotropium in the treatment of COPD: Effects on lung function

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 5, 2009, Pages 404-415

  Cazzola, Mario ^a   Tashkin, Donald P ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combination therapy; COPD; Formoterol; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; METERED DOSE INHALER; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPIROMETRY; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-AGONISTS; ANIMALS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 70350120604     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550903156333     Document Type: Review

References (68)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J2004; 23:932-946.
3. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004; 364:791-802.
4. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004; 117 (Suppl 1):24-32.
5. Canning BJ, Fischer A. Neural regulation of airway smooth muscle tone. Respir Physiol 2001; 125:113-127.
6. Ohrui T, Yanai M, Sekizawa K, Morikawa M, Sasaki H, Takishima T. Effective site of bronchodilation by ß-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992; 146: 88-91.
7. Daniel EE, Kannan M, Davis C, Posey-Daniel V. Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscle. Respir Physiol1986; 63:109-128.
8. Rhoden KJ, Meldrum LA, Barnes PJ. Inhibition of cholinergic neurotransmission in human airways by ß2-adrenoceptors. J Appl Physiol 1988; 65:700-705.
9. Wessler I, Reinheimer T, Brunn G, Anderson GP, Maclagan J, RacḱeK. ß-adrenoceptorsmediate inhibition of (3H)-acetylcholine release from the isolated rat and guinea-pig trachea: role of the airwaymucosa and prostaglandins. Br J Pharmacol 1994; 113:1221-1230.
10. Zhang XY, Olszewski MA, Robinson NE. ß2-Adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. Am J Physiol 1995; 268:L950-956.
11. Belvisi MG, Patel HJ, Takahashi T, Barnes PJ, Giembycz MA. Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br J Pharmacol 1996; 117:1413-1420.
12. de Haas JRA, Terpstra JS, Zaagsma J, Roffel AF. Enhancement of endogenous acetylcholine and norepinephrine release by prejunctional ß2- adrenoceptors in human isolated bronchi (Abstract). Am J Respir Crit Care Med 1998; 157:A723.
13. Zhang XY, Zhu FX, Olszewski MA, Robinson NE. Effects of enantiomers of ß2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998;274:L32- 38.
14. de Haas JR, Terpstra JS, Van der Zwaag M, Kockelbergh PG, Roffel AF, Zaagsma J. Facilitatory ß2-adrenoceptors on cholinergic and adrenergic nerve endings of the guinea pig trachea. Am J Physiol Lung Cell Mol Physiol 1999; 276:L420-425.
15. Kume H, Graziano MP, Kotlikoff MI. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc Natl Acad Sci USA 1992; 89:11051-11055.
16. Patel HJ, Giembycz MA, Keeling JE, Barnes PJ, Belvisi MG. Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calciumactivated potassium channels. J Pharmacol Exp Ther 1998; 286:952-958.
17. Brichetto L, Song P, Crimi E, Rehder K, Brusasco V. Modulation of cholinergic responsiveness through the ß-adrenoceptor signal transmission pathway in bovine trachealis. J Appl Physiol 2003;95:735-741.
18. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest1999; 115:966-971.
19. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a ß-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315:735-739.
20. LeDoux EJ, Morris JF, Temple WP, Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989; 95:1013-1036.
21. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105:1411-1419.
22. Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, McFarland K, Petty TL, Silvers W, Rennard SI, Mueller M, Repsher LH, Zuwallack RL, Vale R. Addition of anticholinergic solution prolongs bronchodilator effect of ß2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996;100:40S-48S.
23. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest1997;112:1514-1521.
24. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641.
25. Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera MG, D'Amato G, Rossi F. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7:103-107. (Pubitemid 24210802)
26. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965.
27. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784.
28. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90:497-499.
29. Sichletidis L, Kottakis J, Marcou S, Constantinidis TC, Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999; 53:185-188.
30. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative doseresponse study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50:62-66.
31. Oren J, Tashkin DP, Gross NJ, et al. A pharmacodynamic doseresponse study of ipratropium bromide in chronic obstructive pulmonary disease (abstract). Am J Respir Crit Care Med 1998; 157:A802.
32. Cazzola M, Matera MG, Di Perna E, Califano C, D'Amato M, Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999; 93:909-911.
33. Cazzola M, Di Perna F, Centanni S, Califano C, Donner CF, D'Amato M, D'Amato G. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999;54:1083-1086
34. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-885.
35. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3- week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119:1347-1356.
36. Casaburi R, Conoscenti CS. Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med2004; 117 (Suppl 1):33-40.
37. Tennant RC, Erin EM, Barnes PJ, Hansel TT. Long-acting ß2- adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 2003; 3:270-276
38. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249- 259.
39. Cazzola M, Matera MG. Long-acting bronchodilators are the firstchoice option for the treatment of stable COPD. Chest 2004; 125:9-11.
40. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
41. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404.
42. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17:35-39.
43. Brashier B, Jantikar A, Maganji M, Raghupathy A, Valsa S, Gokhale P,Mahadik P, Gogtay J, Salvi SS. Addition of formoterol to tiotropium produces better FEV1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD (Abstract). Chest 2005; 128:258s.
44. Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005; 99:524-528.
45. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100:1925-1932.
46. van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19:639-644.
47. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214-222.
48. Gaultier C, Reinberg A, Girard E. Circadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilatators. Respir Physiol 1977; 31:169-182.
49. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509-517.
50. Tashkin D, Pearle J, Iezzoni D, Varghese ST. Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: Findings from a randomized, placebo-controlled trial. J COPD 2009; 6:17-25.
51. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102:1511-1520.
52. Tashkin DP. COPD treatment with formoterol + tiotropium provides a greater improvement in lung function than treatment with tiotropium alone regardless of concomitant ICS use (abstract). Am J Respir Crit Care Med 2008; 177:A961.
53. Tashkin DP, Pearle JL, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium regardless of smoking status in patients with chronic obstructive pulmonary disease (abstract). Chest 2008; 134:103S.
54. Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D'Avelli S. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102:1701-1707.
55. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients: time for re-evaluation? Age Aging 2007; 36:213-218.
56. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16:249-254.
57. Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther 2008; doi:10.1016/j.pupt.2008.07.002.
58. Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. RespirMed 2008; 102:189-197.
59. Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008; 2:199-208.
60. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102:479-487.
61. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. (Pubitemid 46294610)
62. Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/ fluticasone propionate by Gold stage of chronic obstructive pulmonary disease: analysis from the randomized, placebocontrolled TORCH study. Respiratory Research 2009; 10:59 doi: 10.1186/1465-9921-10-59.
63. GSK. Final variation assessment report: Seretide Diskus/Viani Diskus Seretide Evohaler/Viani Evohaler (fluticasone propionate/ salmeterol xinafoate). Available at: www.gsk.com/media/pressreleases/ 2007/2007 07 09 GSK1092.htm. Accessed March 25, 2008.
64. Rabe KF, TimmerW, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255-262.
65. Cazzola M, Matera MG. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101:957-962.
66. Pistolesi, M, Camiciottoli, G, Paoletti, M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102:367-376.
67. Cooper, CB, Tashkin, DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330:640-644.
68. Cazzola M, Matera MG. To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. Chest 2008; 134:223-225.